Alyeska Investment Group
SGP

Alyeska Investment Group’s SpyGlass Pharma SGP Stock Holding History

Alyeska Investment Group’s Portfolio SGP Stock Details SGP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.48M Buy
+57,000
New +$1.53M ﹤0.01% 556

Other funds holding SGP

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Alyeska Investment Group's SGP Position: Q1 2026 in Review

Alyeska Investment Group opened a new position in SpyGlass Pharma (SGP) in Q1 2026: 57,000 shares worth $1.48M. The stake represents ﹤0.01% of the portfolio and ranks #556 among its holdings.

35 funds tracked by Wall St. Rank hold SGP as of Q1 2026.

  • Alyeska Investment Group held 57,000 shares of SpyGlass Pharma worth $1.48M as of Q1 2026.
  • SpyGlass Pharma was a new Alyeska Investment Group position in Q1 2026.
  • SpyGlass Pharma made up ﹤0.01% of Alyeska Investment Group's portfolio in Q1 2026, its #556 holding.
  • 35 funds tracked by Wall St. Rank held SpyGlass Pharma as of Q1 2026.

Based on Alyeska Investment Group's 13F filing for Q1 2026, filed 15 May 2026.